FDA Advisers Back Febuxostat for Gout Despite Possible CV Risk FDA Advisers Back Febuxostat for Gout Despite Possible CV Risk

Febuxostat is appropriate for some patients with gout-related hyperuricemia, the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee said at a joint meeting.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Rheumatology News Source Type: news